ERBB2 and breast carcinoma: Significantly, since its approval by the U.S. FDA in 2013, Kadcyla has been administered to HER2-positive breast cancer patients, delivering effective therapeutic outcomes by amalgamating the advantages of conventional antibody treatments and chemotherapy [50,51].